Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer. Read more about Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis. Read more about The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis.
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Read more about Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy. Read more about What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy.
Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes. Read more about Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Read more about Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Read more about Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy. Read more about Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy.
Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019. Read more about Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Read more about Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
